Bruce Miller
Chief Scientific Officer COPD Foundation
Seminars
Thursday 17th September 2026
A Patient-Inspired Future for COPD Drug Development
9:00 am
- Re-evaluating the primary endpoints in clinical trials to focus on outcomes that are more meaningful to patients’ daily lives and what they truly care about
- Leverage patient-led insights and initiatives to design studies that improve adoption, engagement, and real-world impact
- Capitalise on renewed industry momentum to build collaborative, patient-centric approaches that accelerate more effective COPD therapies
- Hear a direct patient perspective to uncover crucial insights into shaping successful clinical trials and drug development programs
Thursday 17th September 2026
Panel Discussion: Thinking Beyond Exacerbations & Lung Function to Define the Future of Clinical Endpoints
9:30 am
- Should COPD drug development move beyond exacerbation reduction as the dominant endpoint, and what alternative measures could better capture meaningful clinical benefit?
- How clinically meaningful are early improvements in lung function, and could they serve as valid endpoints for evaluating acute COPD treatments?
- What additional endpoints could better reflect patient benefit, including symptom improvement, quality of life, or disease progression?
- How do regulatory expectations currently shape endpoint selection in COPD trials, and where might there be flexibility for innovation?
- What strategies can developers use to demonstrate robust clinical value when proposing novel endpoints to regulators and payers?
